Overview
This study evaluates the feasibility and accuracy of an AI-powered mobile platform (NuvanaDx) for early detection of skin cancer, including melanoma, using smartphone-based imaging. The platform is designed to improve access to early diagnosis, reduce waiting times, and support triage into appropriate care pathways.
Description
The study will collect retrospective and prospective anonymized skin lesion images and metadata to validate the AI algorithm against dermatology-confirmed diagnoses. The aim is to determine sensitivity, specificity, and predictive value of the AI tool across diverse populations and skin tones. The study will also assess user experience, accessibility, and integration into clinical care pathways.
Eligibility
Inclusion Criteria:
Adults (≥18 years) presenting with skin lesions suspicious for malignancy.
Ability to provide informed consent.
Exclusion Criteria:
Inability to provide informed consent.
Poor-quality images unsuitable for AI analysis.